Director Brawley Otis W purchases 35.6K shares of LYEL at $0.56 (initial holding)
BRAWLEY OTIS W, a director, acquired 35,640 shares at $0.56 per share on 2025-03-31, establishing an initial position in Lyell Immunopharma. The purchase occurred at a price well below the current $10.15 and substantially below the 52-week high of $60.20, though the stock is -83.1% from its 52-week peak and -23.3% over the past 30 days. The company is operationally challenged, with quarterly revenue of $34,000.00 against a net loss of $-44,583,000.00, and annual revenue declined -53.1% year-over-year; the company remains unprofitable on a full-year basis. An insider's initial entry into a distressed biotech warrants close examination of both timing context and any concurrent capital or strategic developments, given the magnitude of operational losses relative to revenue.